Acting in the right place at the right time is the key to effective medical treatment with minimal side effects. However, ...

Hitting the target Some of the first-generation WEE1 inhibitors appeared to unintentionally target other cell cycle pathways regulated by the PLK1 and PLK2 kinases. “When we look at the ...

At the recent ASCO Gastrointestinal Cancers symposium, Cyclacel Ltd. presented preclinical data for the Polo-like kinase 1 (PLK1) inhibitor plogosertib from assessment in models of colorectal cancer.

Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 OncoSignature assay designed to detect endometrial cancer patients who can ...